SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines
Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still uncharacterized. Serum or plasma samples from healthy donor...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2215677 |
| _version_ | 1797673022590550016 |
|---|---|
| author | Thomas E. Hickey Troy J. Kemp Jimmie Bullock Aaron Bouk Jordan Metz Abigail Neish James Cherry Douglas R. Lowy Ligia A. Pinto |
| author_facet | Thomas E. Hickey Troy J. Kemp Jimmie Bullock Aaron Bouk Jordan Metz Abigail Neish James Cherry Douglas R. Lowy Ligia A. Pinto |
| author_sort | Thomas E. Hickey |
| collection | DOAJ |
| description | Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still uncharacterized. Serum or plasma samples from healthy donor recipients of either vaccine (BNT162b2 n = 53, mRNA-1273 n = 49; age 23–67), and individuals naturally infected with SARS-CoV-2 (n = 106; age 18–82) were collected 0–2 months post-infection or 1- and 4 months after second dose of vaccination. Anti-Spike antibody levels and avidity were measured via an enzyme-linked immunosorbent assay (ELISA). Overall, vaccination induced higher circulating anti-Spike protein immunoglobulin G (IgG) antibody levels and avidity compared to infection at similar time intervals. Both vaccines produced similar anti-Spike IgG concentrations at 1 month, while mRNA-1273 demonstrated significantly higher circulating antibody concentrations after 4 months. mRNA-1273 induced significantly higher avidity at month 1 compared to BNT162b2 across all age groups. However, the 23–34 age group was the only group to maintain statistical significance by 4 months. Male BNT162b2 recipients were approaching statistically significant lower anti-Spike IgG avidity compared to females by month 4. These findings demonstrate enhanced anti-Spike IgG levels and avidity following vaccination compared to natural infection. In addition, the mRNA-1273 vaccine induced higher antibody levels by 4 months compared to BNT162b2. |
| first_indexed | 2024-03-11T21:39:24Z |
| format | Article |
| id | doaj.art-0a66c134f1764754ac6c6d4cd549e4a5 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:39:24Z |
| publishDate | 2023-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-0a66c134f1764754ac6c6d4cd549e4a52023-09-26T13:25:50ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-08-0119210.1080/21645515.2023.22156772215677SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccinesThomas E. Hickey0Troy J. Kemp1Jimmie Bullock2Aaron Bouk3Jordan Metz4Abigail Neish5James Cherry6Douglas R. Lowy7Ligia A. Pinto8Frederick National Laboratory for Cancer ResearchFrederick National Laboratory for Cancer ResearchFrederick National Laboratory for Cancer ResearchNational Cancer InstituteFrederick National Laboratory for Cancer ResearchFrederick National Laboratory for Cancer ResearchNational Institutes of HealthNational Institutes of HealthFrederick National Laboratory for Cancer ResearchCertain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still uncharacterized. Serum or plasma samples from healthy donor recipients of either vaccine (BNT162b2 n = 53, mRNA-1273 n = 49; age 23–67), and individuals naturally infected with SARS-CoV-2 (n = 106; age 18–82) were collected 0–2 months post-infection or 1- and 4 months after second dose of vaccination. Anti-Spike antibody levels and avidity were measured via an enzyme-linked immunosorbent assay (ELISA). Overall, vaccination induced higher circulating anti-Spike protein immunoglobulin G (IgG) antibody levels and avidity compared to infection at similar time intervals. Both vaccines produced similar anti-Spike IgG concentrations at 1 month, while mRNA-1273 demonstrated significantly higher circulating antibody concentrations after 4 months. mRNA-1273 induced significantly higher avidity at month 1 compared to BNT162b2 across all age groups. However, the 23–34 age group was the only group to maintain statistical significance by 4 months. Male BNT162b2 recipients were approaching statistically significant lower anti-Spike IgG avidity compared to females by month 4. These findings demonstrate enhanced anti-Spike IgG levels and avidity following vaccination compared to natural infection. In addition, the mRNA-1273 vaccine induced higher antibody levels by 4 months compared to BNT162b2.http://dx.doi.org/10.1080/21645515.2023.2215677avidityiggsars-cov-2serologyvaccinesinfectionspike |
| spellingShingle | Thomas E. Hickey Troy J. Kemp Jimmie Bullock Aaron Bouk Jordan Metz Abigail Neish James Cherry Douglas R. Lowy Ligia A. Pinto SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines Human Vaccines & Immunotherapeutics avidity igg sars-cov-2 serology vaccines infection spike |
| title | SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines |
| title_full | SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines |
| title_fullStr | SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines |
| title_full_unstemmed | SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines |
| title_short | SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines |
| title_sort | sars cov 2 igg spike antibody levels and avidity in natural infection or following vaccination with mrna 1273 or bnt162b2 vaccines |
| topic | avidity igg sars-cov-2 serology vaccines infection spike |
| url | http://dx.doi.org/10.1080/21645515.2023.2215677 |
| work_keys_str_mv | AT thomasehickey sarscov2iggspikeantibodylevelsandavidityinnaturalinfectionorfollowingvaccinationwithmrna1273orbnt162b2vaccines AT troyjkemp sarscov2iggspikeantibodylevelsandavidityinnaturalinfectionorfollowingvaccinationwithmrna1273orbnt162b2vaccines AT jimmiebullock sarscov2iggspikeantibodylevelsandavidityinnaturalinfectionorfollowingvaccinationwithmrna1273orbnt162b2vaccines AT aaronbouk sarscov2iggspikeantibodylevelsandavidityinnaturalinfectionorfollowingvaccinationwithmrna1273orbnt162b2vaccines AT jordanmetz sarscov2iggspikeantibodylevelsandavidityinnaturalinfectionorfollowingvaccinationwithmrna1273orbnt162b2vaccines AT abigailneish sarscov2iggspikeantibodylevelsandavidityinnaturalinfectionorfollowingvaccinationwithmrna1273orbnt162b2vaccines AT jamescherry sarscov2iggspikeantibodylevelsandavidityinnaturalinfectionorfollowingvaccinationwithmrna1273orbnt162b2vaccines AT douglasrlowy sarscov2iggspikeantibodylevelsandavidityinnaturalinfectionorfollowingvaccinationwithmrna1273orbnt162b2vaccines AT ligiaapinto sarscov2iggspikeantibodylevelsandavidityinnaturalinfectionorfollowingvaccinationwithmrna1273orbnt162b2vaccines |